Developer docs
API playgroundTry for free, no card

Search company profiles

SipNose

Full company profile

uuid000ew6t

Namestring
SipNose
Legal namestring
SipNose Nasal Delivery Systems
Websiteurl
sipnose.com
Company typeenum
Private
Founded yearint
2011
Short descriptiontext

SipNose was an Israeli medical device company (founded 2011) that developed proprietary intranasal drug delivery devices for nose-to-brain administration of CNS therapeutics. Its technology assets were acquired by Aptar Pharma in October 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersYoqne`am `illit, Israel
HQ citystring
Yoqne`am `illit
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
nasal drug delivery, intranasal drug delivery, nose-to-brain delivery, CNS therapeutics devices, pharmaceutical delivery devices
Industry1 code
1Nasal Drug Delivery Devices (Sprays/Powder Devices)
CodeHLAHAIAKPrimaryYes
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Drug Delivery Devices
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SipNose developed proprietary intranasal drug delivery devices designed to enable targeted delivery of pharmaceutical compounds through the nasal passage for local, systemic, and central nervous system (CNS) indications. The technology was specifically engineered for nose-to-brain administration, providing a non-invasive route to deliver therapeutics directly to the brain while bypassing the blood-brain barrier. SipNose's device technology assets were acquired by Aptar Pharma in October 2024.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1SipNose Nasal Delivery Systems
CategoryDrug Delivery Devices
Description

Intranasal drug delivery devices designed for nose-to-brain and CNS therapeutics, enabling targeted delivery of pharmaceutical compounds through the nasal passage. The platform addresses local, systemic, and central nervous system indications and provides a non-invasive route to deliver therapeutics directly to the brain, bypassing the blood-brain barrier. Targeted at pharmaceutical and biotech companies developing CNS and intranasal drugs.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Aptar Pharma
Strategic tierCoreTypeOthersAnnounced on2024-10-01
Description

In October 2024, Aptar Pharma acquired the device technology assets of Israeli company SipNose Nasal Delivery Systems. This acquisition was specifically made to expand Aptar Pharma's intranasal drug delivery capabilities, particularly for nose-to-brain and CNS therapeutics applications.

Peers10 records
1Stevanato Group
TypeBroad incumbent
Description

Stevanato Group provides drug containment, delivery device, and diagnostic solutions to the pharmaceutical industry, comparable to SipNose as a participant in the drug delivery devices value chain.

2OptiNose
TypeDirect peer
Description

OptiNose develops proprietary nasal drug delivery platforms (e.g., XHANCE) for targeted therapy, directly comparable to SipNose's focus on intranasal delivery for therapeutic indications including CNS-adjacent applications.

3Aptar Pharma
TypeBroad incumbent
Description

Aptar Pharma is a global leader in drug delivery systems (nasal, injectable, eye care) and acquired SipNose's device technology assets in October 2024, making it the most directly relevant broad incumbent and acquirer of SipNose's IP.

4Nemera
TypeDirect peer
Description

Nemera manufactures nasal and pulmonary drug delivery devices (spray pumps, nebulizers) and competes directly with SipNose in intranasal device technology for pharmaceutical partners.

5Kurve Technology
TypeEmerging player
Description

Kurve Technology develops controlled-intranasal delivery platforms (ViaNase) targeting neurological conditions, overlapping with SipNose's nose-to-brain CNS focus as an emerging peer in the same therapeutic delivery niche.

6Becton, Dickinson and Company (BD)
TypeBroad incumbent
Description

BD is a large medical technology company with a Pharmaceutical Systems segment producing drug delivery devices (including nasal and injectable), making it a broad incumbent competing in the same end markets as SipNose.

7West Pharmaceutical Services
TypeOthers
Description

West supplies drug containment and delivery components (closures, devices, injectors) used by pharmaceutical manufacturers, making it a comparable enabling/supply participant in the broader drug delivery ecosystem where SipNose operates.

8Ypsomed
TypeBroad incumbent
Description

Ypsomed develops and manufactures injection and metering systems for self-administration, serving pharma customers — comparable to SipNose as a specialized drug delivery device maker targeting partner pharma programs.

9Gerresheimer
TypeOthers
Description

Gerresheimer manufactures specialty glass and plastic packaging plus drug delivery devices (including nasal/ophthalmic) for pharma customers, comparable to SipNose as an adjacent supplier in the drug delivery devices market.

10Catalent
TypeBroad incumbent
Description

Catalent is a large CDMO offering drug delivery and manufacturing solutions (including nasal and inhaled formats) to pharma and biotech customers, comparable to SipNose's end customers and adjacent to its delivery-device value chain.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SipNose

Drug Delivery Devicessipnose.com

SipNose was an Israeli medical device company (founded 2011) that developed proprietary intranasal drug delivery devices for nose-to-brain administration of CNS therapeutics. Its technology assets were acquired by Aptar Pharma in October 2024.

SipNose firmographics

Firmographics
Name
SipNose
Legal name
SipNose Nasal Delivery Systems
Website
https://sipnose.com
Company type
Private
Founded year
2011
Operating status
Acquired
Headcount range
1–10 employees
Short description
SipNose was an Israeli medical device company (founded 2011) that developed proprietary intranasal drug delivery devices for nose-to-brain administration of CNS therapeutics. Its technology assets were acquired by Aptar Pharma in October 2024.
Ownership category
akta.pro rank

SipNose industry classification

Industry
Product category
Drug Delivery Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

  • Nasal drug delivery
  • Intranasal drug delivery
  • Nose-to-brain delivery
  • CNS therapeutics devices
  • Pharmaceutical delivery devices

Where SipNose is headquartered

Location

Headquarters

HQ city
Yoqne`am `illit
HQ country
Israel
HQ region
Middle East

Markets served

SipNose business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

SipNose product offering

Product offering

Core offering

SipNose developed proprietary intranasal drug delivery devices designed to enable targeted delivery of pharmaceutical compounds through the nasal passage for local, systemic, and central nervous system (CNS) indications. The technology was specifically engineered for nose-to-brain administration, providing a non-invasive route to deliver therapeutics directly to the brain while bypassing the blood-brain barrier. SipNose's device technology assets were acquired by Aptar Pharma in October 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • SipNose Nasal Delivery Systems Intranasal drug delivery devices designed for nose-to-brain and CNS therapeutics, enabling targeted delivery of pharmaceutical compounds through the nasal passage. The platform addresses local, systemic, and central nervous system indications and provides a non-invasive route to deliver therapeutics directly to the brain, bypassing the blood-brain barrier. Targeted at pharmaceutical and biotech companies developing CNS and intranasal drugs.

Companies that use SipNose

Customer profile

Segments1 record

Ideal customer profiles1 record

SipNose technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

SipNose partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Aptar PharmacoreOthers · 1 October 2024In October 2024, Aptar Pharma acquired the device technology assets of Israeli company SipNose Nasal Delivery Systems. This acquisition was specifically made to expand Aptar Pharma's intranasal drug delivery capabilities, particularly for nose-to-brain and CNS therapeutics applications.

Scale indicators1 record

SipNose competitors and assessment

Company assessment

Broad incumbents

  • Stevanato Group: Stevanato Group provides drug containment, delivery device, and diagnostic solutions to the pharmaceutical industry, comparable to SipNose as a participant in the drug delivery devices value chain.
  • Aptar Pharma: Aptar Pharma is a global leader in drug delivery systems (nasal, injectable, eye care) and acquired SipNose's device technology assets in October 2024, making it the most directly relevant broad incumbent and acquirer of SipNose's IP.
  • Becton, Dickinson and Company (BD): BD is a large medical technology company with a Pharmaceutical Systems segment producing drug delivery devices (including nasal and injectable), making it a broad incumbent competing in the same end markets as SipNose.
  • Ypsomed: Ypsomed develops and manufactures injection and metering systems for self-administration, serving pharma customers — comparable to SipNose as a specialized drug delivery device maker targeting partner pharma programs.
  • Catalent: Catalent is a large CDMO offering drug delivery and manufacturing solutions (including nasal and inhaled formats) to pharma and biotech customers, comparable to SipNose's end customers and adjacent to its delivery-device value chain.

Direct peers

  • OptiNose: OptiNose develops proprietary nasal drug delivery platforms (e.g., XHANCE) for targeted therapy, directly comparable to SipNose's focus on intranasal delivery for therapeutic indications including CNS-adjacent applications.
  • Nemera: Nemera manufactures nasal and pulmonary drug delivery devices (spray pumps, nebulizers) and competes directly with SipNose in intranasal device technology for pharmaceutical partners.

Emerging players

  • Kurve Technology: Kurve Technology develops controlled-intranasal delivery platforms (ViaNase) targeting neurological conditions, overlapping with SipNose's nose-to-brain CNS focus as an emerging peer in the same therapeutic delivery niche.

Others

  • West Pharmaceutical Services: West supplies drug containment and delivery components (closures, devices, injectors) used by pharmaceutical manufacturers, making it a comparable enabling/supply participant in the broader drug delivery ecosystem where SipNose operates.
  • Gerresheimer: Gerresheimer manufactures specialty glass and plastic packaging plus drug delivery devices (including nasal/ophthalmic) for pharma customers, comparable to SipNose as an adjacent supplier in the drug delivery devices market.

Market position

Customer concentration

SipNose social profiles

Digital presence

SipNose financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SipNose leadership team

Management profile

Number of profiles

Profiles2 records

SipNose funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SipNose M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SipNose

What does SipNose do?

SipNose developed proprietary intranasal drug delivery devices designed to enable targeted delivery of pharmaceutical compounds through the nasal passage for local, systemic, and central nervous system (CNS) indications. The technology was specifically engineered for nose-to-brain administration, providing a non-invasive route to deliver therapeutics directly to the brain while bypassing the blood-brain barrier. SipNose's device technology assets were acquired by Aptar Pharma in October 2024.

When was SipNose founded?

SipNose was founded in 2011. It employs 1 to 10 people.

Where is SipNose based?

SipNose is headquartered in Yoqne`am `illit, Israel, in the Middle East region.

Who are SipNose's main competitors?

Broad incumbents on record are Stevanato Group, Aptar Pharma, Becton, Dickinson and Company (BD), Ypsomed and Catalent. Direct peers are OptiNose and Nemera. Kurve Technology is listed as an emerging player. Others are West Pharmaceutical Services and Gerresheimer.

Does SipNose have an API?

No public API is recorded for SipNose.

What industry is SipNose in?

SipNose's product category is Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals